Healthcare Sector Analytics

Market size, company revenue, drug approvals, clinical trials, regulation, hospitals, doctors, drug spending, labs and devices

Brand drugFirst approved 2012

Myrbetriq(Mirabegron)Astellas Pharma Inc. logo4503.T

Medicare prescription drug cost, prescriptions and prescribers, 2024 · made by Astellas Pharma Inc.

$2.30B

Medicare cost, 2024

Medicare drug plans spent $2.3 billion on Myrbetriq (mirabegron) in 2024, for 3.5 million prescriptions and refills filled by 762,665 patients. It ranks 19th among all drugs by Medicare drug plan spending. California accounts for the most spending ($207.7 million, 9% of the total). It is made by Astellas Pharma Inc. (4503.T).

Medicare cost, 2024

$2.30B

-8.5% from 2023

Prescriptions

3.5M

$665.20 per claim

Patients

763K

192,430 prescribers

Total spending, 2024

$2.30B

$3,010.74 per patient

Questions and answers

How much does Medicare spend on Myrbetriq?

Medicare prescription drug plans paid $2.30B for Myrbetriq in 2024, for 3,451,931 prescriptions and refills to 762,665 patients (down 8.5% from 2023). The average cost per claim was $665.20.

Which state spends the most on Myrbetriq?

California had the highest Medicare cost for Myrbetriq in 2024: $207.7M for 287,532 claims, followed by Texas ($194.1M).

Who prescribes Myrbetriq the most?

Emily A Levandusky, physician assistant in Cheektowaga, NY, had the highest Medicare cost for Myrbetriq in 2024: 2,740 claims costing $2.1M.

Who makes Myrbetriq?

Myrbetriq is made by Astellas Pharma Inc. (4503.T), listed in the Medicare spending data as Astellas Pharma.

Spending over the years

Medicare spending by year

All plans and makers

Prescriber data: cost by year

Medicare spending on Myrbetriq was $2.30B in 2024, after a high of $2.51B in 2023.

By state

Where the prescribers practice, 2024

Medicare cost by state

States with the highest cost

Top prescribers of Myrbetriq, 2024

By Medicare drug cost

PrescriberTypeClaimsPatientsCost
Emily A Levandusky Cheektowaga, NYPhysician Assistant2,740784$2.1M
Brian C Crotzer Cheektowaga, NYPhysician Assistant1,981638$1.4M
Armen A Kassabian Burbank, CAUrology1,986334$914K
Qingwei R Yan Oakland, CAUrology772219$806K
Peter C Howard Toms River, NJUrology766236$788K
Ghazaleh Rostami Nia Skokie, ILObstetrics & Gynecology830283$771K
Felix CHI-Ming Yip Monterey Park, CAUrology1,225306$766K
Nancy L Wilcox Rochester, NYNurse Practitioner1,071282$744K
Joel Lee Boston, MAPhysician Assistant816225$737K
Richard D Cespedes Easton, MDUrology1,186233$722K
Carlos A Fonseca-Salgado San Juan, PRObstetrics & Gynecology808279$697K
Victor Hartanto Midland Park, NJUrology812212$695K
Benjamin J Haylett Williamsville, NYPhysician Assistant1,131282$682K
Brett D Lebed Santa Maria, CAUrology619218$643K
Manish Gopal Somerset, NJObstetrics & Gynecology992230$626K
James E Renehan Tallahassee, FLUrology748201$602K
Elizabeth A Kavaler New York, NYUrology881246$573K
Melissa C Fischer Royal Oak, MIUrology582203$563K
David E Burday Tallahassee, FLUrology634158$558K
Benjamin C Peng New York, NYUrology518168$543K
Robert W Lobel Albany, NYObstetrics & Gynecology491146$539K
Paul M Littman Hackettstown, NJObstetrics & Gynecology695210$535K
Michelle Buscemi Skokie, ILCertified Nurse Midwife557182$529K
Jessica A Witter Davenport, IANurse Practitioner768168$521K
Scott A Macdiarmid Greensboro, NCUrology750186$518K

Prescriber data by year

YearPrescribersClaimsPatientsCost
2022176,3873,457,934716,053$2.25B
2023189,3723,650,058769,612$2.51B
2024192,4303,451,931762,665$2.30B

Makers, 2024

Spending by manufacturer as listed in the spending data

ManufacturerClaimsSpending
Astellas Pharma4503.T logo4503.T3,453,189$2.30B

Medicaid spending by quarter

Amount reimbursed by state Medicaid programs, all states

Amount reimbursed

Codes

National drug codes (packages)
7
RxNorm concept IDs
1300791, 1300797, 1300801, 1300803, 2541233
Application numbers
NDA202611, NDA213801

More drugs: Medicare drug spending and the Prescriptions view.

Official US government data on Medicare prescription drug plans (Part D) and Medicaid drug use. Cost and spending are before the rebates drug makers pay. Prescribers with fewer than 11 claims of the drug are not published.

LinkedInLinkedInXXYouTubeYouTube